Cover |
3 Months Ended |
|---|---|
Mar. 31, 2025 | |
| Entity Addresses [Line Items] | |
| Document Type | POS AM |
| Amendment Flag | true |
| Amendment Description | On April 4, 2024, bioAffinity Technologies, Inc. (the “Company”) filed a Registration Statement on Form S-1 (Registration No. 333-278512), which was subsequently declared effective by the SEC on April 15, 2024 (the “April 2024 Registration Statement”).On September 11, 2024, the Company filed a Registration Statement on Form S-1 (Registration No. 333-282045), which was subsequently declared effective by the SEC on September 19, 2024 (the “September 2024 Registration Statement”). On November 27, 2024, the Company filed a Registration Statement on Form S-1 (Registration No. 333-283521), which was subsequently declared effective by the SEC on December 6, 2024. Pursuant to Rule 429 under the Securities Act, the prospectus contained in this Registration Statement will be used as a combined prospectus in relation with (i) this Registration Statement, (ii) the April 2024 Registration Statement, and (iii) the September 2024 Registration Statement (the registration statements referenced in clauses (i), (ii) and (iii) collectively referred to as the “2024 Resale Registration Statements”). This Registration Statement constitutes Post-Effective Amendment No. 1 to this Registration Statement, constitutes Post-Effective Amendment No. 1 to the April 2024 Registration Statement, and constitutes Post-Effective Amendment No. 1 to the September 2024 Registration Statement. Such Post-Effective Amendments will become effective concurrently with the effectiveness of this Registration Statement in accordance with Section 8(c) of the Securities Act. This filing is being made to: (i) combine the prospectuses included in the 2024 Resale Registration Statements pursuant to Rule 429 of the Securities Act, and (ii) serve as a Section 10(a)(3) update to the 2024 Resale Registration Statements and to make certain other updates to the prospectus that forms a part of this Post-Effective Amendment. Pursuant to Rule 416 under the Securities Act, there are also being registered such securities that may be issued because of events such as recapitalizations, stock dividends, stock splits and reverse stock splits, and similar transactions. No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the 2024 Resale Registration Statements, as applicable. |
| Entity Registrant Name | bioAffinity Technologies, Inc. |
| Entity Central Index Key | 0001712762 |
| Entity Tax Identification Number | 46-5211056 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 3300 Nacogdoches Road |
| Entity Address, Address Line Two | Suite 216 |
| Entity Address, City or Town | San Antonio |
| Entity Address, State or Province | TX |
| Entity Address, Postal Zip Code | 78217 |
| City Area Code | (210) |
| Local Phone Number | 698-5334 |
| Entity Filer Category | Non-accelerated Filer |
| Entity Small Business | true |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | false |
| Business Contact [Member] | |
| Entity Addresses [Line Items] | |
| Entity Address, Address Line One | 3300 Nacogdoches Road |
| Entity Address, Address Line Two | Suite 216 |
| Entity Address, City or Town | San Antonio |
| Entity Address, State or Province | TX |
| Entity Address, Postal Zip Code | 78217 |
| City Area Code | (210) |
| Local Phone Number | 698-5334 |
| Contact Personnel Name | Maria Zannes |